JPMorgan Chase & Co. Buys 1,394,839 Shares of Elanco Animal Health Incorporated $ELAN

JPMorgan Chase & Co. raised its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 266.4% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,918,336 shares of the company’s stock after buying an additional 1,394,839 shares during the quarter. JPMorgan Chase & Co. owned about 0.39% of Elanco Animal Health worth $38,635,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. AlphaQuest LLC increased its holdings in shares of Elanco Animal Health by 13.7% in the third quarter. AlphaQuest LLC now owns 5,953 shares of the company’s stock worth $120,000 after purchasing an additional 718 shares during the period. Jones Financial Companies Lllp grew its holdings in shares of Elanco Animal Health by 15.2% during the third quarter. Jones Financial Companies Lllp now owns 6,065 shares of the company’s stock worth $119,000 after purchasing an additional 798 shares in the last quarter. MTM Investment Management LLC increased its position in shares of Elanco Animal Health by 5.5% in the second quarter. MTM Investment Management LLC now owns 15,268 shares of the company’s stock worth $218,000 after purchasing an additional 800 shares during the last quarter. Whittier Trust Co. of Nevada Inc. raised its stake in Elanco Animal Health by 80.3% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after purchasing an additional 900 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its position in Elanco Animal Health by 79.3% during the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock valued at $43,000 after purchasing an additional 951 shares during the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently commented on ELAN. Leerink Partners increased their price target on shares of Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a report on Tuesday. Barclays began coverage on shares of Elanco Animal Health in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 target price for the company. Piper Sandler upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and raised their price target for the company from $24.00 to $30.00 in a research report on Thursday, January 22nd. Zacks Research cut Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. Finally, UBS Group increased their price objective on Elanco Animal Health from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Elanco Animal Health has a consensus rating of “Moderate Buy” and an average target price of $27.67.

Elanco Animal Health Stock Up 0.6%

ELAN opened at $26.35 on Friday. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $27.72. The company has a current ratio of 2.17, a quick ratio of 1.23 and a debt-to-equity ratio of 0.60. The business’s 50-day moving average price is $24.23 and its 200-day moving average price is $21.76. The company has a market cap of $13.10 billion, a P/E ratio of -54.90, a P/E/G ratio of 3.38 and a beta of 1.87.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.02. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.Elanco Animal Health’s revenue for the quarter was up 12.2% compared to the same quarter last year. During the same period last year, the company earned $0.14 EPS. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. On average, equities analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Insider Activity

In other news, insider Rajeev A. Modi acquired 4,500 shares of the firm’s stock in a transaction on Thursday, December 11th. The shares were purchased at an average price of $21.33 per share, for a total transaction of $95,985.00. Following the completion of the transaction, the insider owned 123,082 shares of the company’s stock, valued at $2,625,339.06. The trade was a 3.79% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lawrence Erik Kurzius acquired 10,000 shares of the stock in a transaction dated Friday, December 12th. The shares were purchased at an average cost of $21.30 per share, with a total value of $213,000.00. Following the completion of the purchase, the director owned 131,773 shares of the company’s stock, valued at approximately $2,806,764.90. The trade was a 8.21% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 43,450 shares of company stock valued at $937,883 in the last three months. Corporate insiders own 0.89% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.